Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: How Vaccines Stack Up Against Variants So Far

Boehringer Ingelheim Drops ARDS Drug

Executive Summary

Plus: Sanofi is getting into the mRNA vaccine game under a partnership with Translate Bio but has a lot of catching up to do.

You may also be interested in...



Merck’s COVID-19 Therapeutic Development Path Gets A Little Harder

After backing off of MRK-7110 for hospitalized patients the company’s focus is on the oral antiviral molnupiravir for outpatients – which would be a huge win, but the drug has yet to fully prove itself in the clinic.

Sanofi Goes Big On Asia Vaccines With Singapore Investment

French giant makes its biggest single investment to date in Asia as it prepares to build up regional vaccine production capacity, in part to help prepare for future pandemics. 

Incyte Pins Hopes On Phase III Jakafi Analysis In COVID-19 ARDS

Drugs for ARDS in COVID-19 have yielded mixed results in the clinic, with Boehringer Ingelheim pulling one from Phase II development earlier this month.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143988

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel